Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.41 |
| ▸ | RAF1 | P04049 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 3/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10185220 | 0.92 | EPHX2 (0.43) | EPHX2HRH3DGAT1SOAT1CHRM2 | |
| SCHEMBL10185227 | 0.91 | EPHX2 (0.42) | EPHX2RAF1DGAT1CCR3HRH1 | |
| SCHEMBL10184913 | 0.90 | CCR3 (0.46) | HRH3DGAT1SOAT1CCR3HRH1 | |
| SCHEMBL10186415 | 0.90 | EPHX2 (0.47) | EPHX2RAF1DGAT1NOTUMPTGDR2 | |
| SCHEMBL10186158 | 0.88 | CHRM2 (0.41) | EPHX2HRH3CHRM2CHRM5CHRM1 | |
| SCHEMBL10184402 | 0.88 | HRH3 (0.45) | HRH3DGAT1SOAT1CCR3CHRM1 | |
| SCHEMBL10185066 | 0.87 | EPHX2 (0.43) | EPHX2HRH3DGAT1SOAT1PTGDR2 | |
| SCHEMBL10184422 | 0.87 | EPHX2 (0.42) | EPHX2HRH3DGAT1SOAT1CHRM2 | |
| SCHEMBL10185228 | 0.87 | HRH3 (0.40) | HRH3DGAT1SOAT1CCR3PTGDR2 | |
| SCHEMBL10184982 | 0.86 | SCN9A (0.42) | EPHX2HRH3DGAT1SOAT1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | EPHX2 1718/4885RAF1 4751/4885HRH3 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.